InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,433.74
(
0.23%
)
US TECH 100
19,110.80
(
0.22%
)
Dow Jones
38,647.10
(
-0.17%
)
Brent Oil
82.03
(
0.07%
)
Bitcoin
67,096.77
(
0.51%
)
Post# of 58465
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

echipaway

Send PM Follow Ignore
Followers 0
Posts 88
Boards Moderated 0
Alias Born 05/27/2009

echipaway

Re: None

Monday, 10/26/2009 10:56:07 AM

Monday, October 26, 2009 10:56:07 AM

Post# of 58465
28 Days away >>>>>Monday November 23, 2009 trading day after Annual 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, Berlin, Germany November 19-21, 2009.

Agenda
Update of clinical trials in melanoma
http://melanomacongress2009.org/index.php?site=1.3
8:00 - 10:00 Symposium IX Saturday, November 21st
Sanjiv Agarwala
Bethlehem, USA Oblimersen (BCL-2 antisense)

Poster Exhibition/ Poster List (Total 51 so Far)
http://melanomacongress2009.org/index.php?site=9.2
34. Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma and normal LDH
A.C. Pavlick, P.A. Ott, K. Madden, R Kannan, C. Sorlie, C. Escano, S. Mendoza, B. Dubose, H. Yee and L. Liebes
NYU Cancer Institute, NYU School of Medicine, New York, NY USA

51. Oblimersen in advanced merkel cell carcinoma: A case study
KY Chung, S Novick
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Genta Incorporated, Berkeley Heights, NJ, USA
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up